Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05906732 · ClinicalTrials.gov registry record · Phase 1
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
A Phase 1 study, sponsored by Thryv Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT05906732 is a Phase 1 study that was terminated before completion, run by Thryv Therapeutics. The registered enrollment target is 42 participants.
The verdict
NCT05906732, a Phase 1 study, was terminated before completion, sponsored by Thryv Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
Part 1: This is a Phase 1b, randomized, double-blind, crossover, dose escalation, placebo-controlled study to evaluate the effect of oral LQT-1213 on dofetilide-induced QTc prolongation in healthy adult subjects. This is a 2-treatment, 2-period crossover study with approximately up to 28 healthy subjects, with screening procedures within 28 days of enrolment. Part 2: This is a Phase 2a, single-blind, placebo run-in, multiple-dose safety study to evaluate the safety, tolerability, and PK of LQT-1213 in patients diagnosed with LQT2 or LQT3. Up to 12 participants with LQT2 and up to 12 participants with LQT3 will be recruited.
Interventions
- DRUG Placebo
- DRUG LQT-1213
- DRUG Dofetilide 250 μg Cap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-03-12 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05906732
The ClinicalTrials.gov registry entry for NCT05906732 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thryv Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05906732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05906732 about?
NCT05906732 is a clinical study titled "Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).". Part 1: This is a Phase 1b, randomized, double-blind, crossover, dose escalation, placebo-controlled study to evaluate the effect of oral LQT-1213 on dofetilide-induced QTc prolongation in healthy adult subjects. This is a 2-treatment, 2-period crossover study with approximately up to 28 healthy sub...
What is the current status of trial NCT05906732?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-03-12. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT05906732?
The interventions under investigation include: Placebo (DRUG), LQT-1213 (DRUG), Dofetilide 250 μg Cap (DRUG).
Who is sponsoring clinical trial NCT05906732?
This trial is sponsored by Thryv Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.